Back to MBLX
Robbins Umeda LLP Announces the Filing of a Class Action Lawsuit Against Metabolix, Inc.

Shareholder rights firm Robbins Umeda LLP announces the filing of a federal securities class action by an investor in the United States District Court for the District of Massachusetts on behalf of purchasers of Metabolix, Inc. (NASDAQ: MBLX) shares between March 10, 2010 and January 12, 2012 (the "Class Period").

Metabolix is a bioscience company that claims to focus on bringing environmentally friendly solutions to the plastics, chemicals and energy industries. The company's largest platform, commercialized through Telles LLC, a joint venture with Archer-Daniels-Midland Company ("ADM"), is a polyhydroxyalkanoate ("PHA") bioplastics product called Mirel. Through Telles, Metabolix promoted these bioplastics as biobased and biodegradable, but functionally equivalent, alternatives to petroleum-based plastics.

The complaint alleges that during the Class Period, certain officers at Metabolix issued a series of false and misleading statements to investors regarding the company's business and prospects. Specifically, it is alleged that officers misrepresented and/or failed to disclose that: (1) the company's Telles joint venture with ADM would not meet its commercial phase benchmark as early as mid-2010, or even in 2011, and that as a result the company would not receive royalties or payments from services related to Telles; (2) that Mirel was not a commercially viable product that would offer value to Metabolix and its shareholders; and (3) that as a result of these facts, Metabolix and its officers lacked a reasonable basis for their positive statements about the company and its prospects.

On January 12, 2012, Metabolix issued a press release announcing that ADM had given notice that it was terminating the Telles joint venture. ADM disclosed that their decision was the result of uncertainty about Telles' projected capital and production costs, ongoing concerns about the rate of market adoption of the venture's products, and the inability of the joint venture to deliver sufficient results in a reasonable time frame. On this news, shares of Metabolix declined by approximately 57% to close on January 13, 2012, at a multi-year low of only $2.54 per share.

Concerned shareholders who would like more information about their rights and potential remedies can contact Robbins Umeda attorney Gregory E. Del Gaizo at (800) 350-6003, info@robbinsumeda.com, or via the shareholder information form on the firm's website.

Robbins Umeda LLP is a nationally recognized leader in securities litigation and shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. For more information, please go to http://www.robbinsumeda.com.

Press release link: http://www.robbinsumeda.com/shareholders-rights-blog/metabolix-inc/

Attorney Advertising. Past results do not guarantee a similar outcome.

(c) 2014 Business Wire, Inc., All rights reserved. All of the news releases and other content contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. Any copying or reproduction (other than for an individual user's personal reference), redistribution, reposting or other transmission or communication is expressly prohibited without prior written permission of Business Wire, Inc
Back to MBLX
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki